As well as holding the deputy chair position on the board of Orphazyme, Bo Jesper Hansen is something of a celebrity within the treatment of rare diseases, having also co-founded Swedish Orphan Biovitrium, Sobi.
Hansen sold his shares in Swedish Orphan Biovitrium, Sobi in 2016 and stepped down from the board, and has been on the board of Danish biotech company Orphazyme since 2010, observing the development of arimoclomol, which has been submitted to both the FDA and EMA for approval as a treatment for rare metabolic disease Niemann-Pick type C (NPC).
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Long wait for IVDR implementation is over, putting an end to pandemic "wild west"
After prolonged debates on potential bottlenecking and supply issues, the EU’s long-awaited In Vitro Diagnostic Medical Devices Regulation comes into force on May 26.
GN purchase story is very speculative, says analyst
Competition rules could block a purchase of GN Store Nord and subsequent divestment of GN Hearing, says a Sydbank analyst on the speculative story that this might be underway.
Bavarian Nordic upgrades guidance following vaccine contract
Bavarian has been the center of attention in recent days due to its monkeypox vaccine, and the company has now secured a vaccine contract with another undisclosed country. Consequently, Bavarian has raised its expectations for the full year.
Novo Nordisk invests additional millions of dollars in new manufacturing facilities
Novo Nordisk’s DKK 17bn (USD 2.4bn) investment into upgrading and building new facilities in Kalundborg last year has now been followed by a DKK 1bn (USD 143.8m) investment in the same location.
US to start using Bavarian vaccine stockpile
In an attempt to contain a monkeypox outbreak, US authorities will start offering certain people Bavarian Nordic-developed Jynneos vaccinations against the infectious disease.
Director Global Engineering 
Senior Chemical Safety Advisor 
System Sales Development Consultant - Investment Projects, Merck Millipore 
Account Manager 
Production Director 
Senior IT Network Engineer 
Key Account Manager, Europe and Asia 
Clinical Trial Manager for development of in vitro diagnostics 
2 Sales Representatives and Product Specialists 
Senior QA Specialist 
Strategic Procurement Manager, Direct Spend (Category Manager) 
Project Manager & Scrum Master 
Senior Manager, Clinical Trial Budget 
Senior Project Manager (GMP - Life Science) 
Cell Culture Scientist/Senior Scientist 
Nordic Medical Affairs Manager 
CMO Operations Specialist - screening & selection of CMO/CDMO’s